Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $30,034.80 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of the company’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the sale, the general counsel now owns 486,027 shares of the company’s stock, valued at approximately $7,086,273.66. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46.

Liquidia Trading Up 1.2 %

Shares of NASDAQ LQDA traded up $0.16 during mid-day trading on Wednesday, hitting $13.74. The company had a trading volume of 426,187 shares, compared to its average volume of 943,607. The company has a market capitalization of $1.04 billion, a PE ratio of -11.45 and a beta of 0.16. The firm has a 50-day simple moving average of $14.77 and a two-hundred day simple moving average of $10.88. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The company had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. Sell-side analysts expect that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently made changes to their positions in LQDA. Findell Capital Management LLC bought a new stake in shares of Liquidia during the fourth quarter worth approximately $25,095,000. State Street Corp boosted its stake in Liquidia by 861.0% during the second quarter. State Street Corp now owns 1,448,211 shares of the company’s stock worth $6,314,000 after acquiring an additional 1,297,509 shares in the last quarter. Vestal Point Capital LP bought a new stake in Liquidia during the fourth quarter worth about $12,331,000. Kynam Capital Management LP boosted its stake in Liquidia by 34.9% during the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after acquiring an additional 698,324 shares in the last quarter. Finally, Beryl Capital Management LLC bought a new stake in Liquidia during the third quarter worth about $3,135,000. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on LQDA. LADENBURG THALM/SH SH upped their target price on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Bank of America upped their price objective on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. Wedbush reiterated an “underperform” rating and set a $3.00 target price on shares of Liquidia in a report on Thursday, December 21st. Finally, HC Wainwright increased their target price on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).